"We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma," says Teona Iarajuli.
In this video, Teona Iarajuli discusses the background and findings from her study, “Does utilizing IRIS, a segmented three-dimensional model, preserve renal parenchymal volume during robotic partial nephrectomy?”, which was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Iarajuli is a fourth year medical student at Hackensack Meridian School of Medicine in New Jersey.
Video Transcript:
Could you describe the background for this study?
IRIS is a 3D anatomical model that is interactive, and it's actually made out of CT scans. It gives you an ability to rotate and directly pull the tumor out of the kidney during the surgery. It gives you a much better visual field during partial nephrectomy. So, our goal in our study was to find out does IRIS actually help us to preserve renal parenchyma in high nephrometry score complicated cases during partial nephrectomy.
What were some of the notable findings?
We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma via making the surgery more precise, compared to non-IRIS patients. I just want to emphasize that using this 3D model of IRIS does have a potential to improve patient outcomes post-partial nephrectomy, especially by preserving more renal parenchyma and also just making the surgery much more precise than without IRIS.
This transcription has been edited for clarity.
FDA expert reviews data supporting belzutifan approval for VHL-associated kidney cancer
November 16th 2023Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.